pdufa.bio
Home › Decisions › TEVA 2026-03-30

TEVA FDA decision — Mar 30, 2026

✓ APPROVED

Teva Pharmaceutical Industries Limited A — PONLIMSI (denosumab-adet) (biosimilar to Pro.

Run-up into the decision (T-120 → T+5)

PDUFA 3/30/26$36.25$18.9510/13/25
Daily close, T-120 (10/13/25) through T+5. Run-up high $36.25 on 2/4/26, low $18.95 on 10/31/25 (T-120 to T-1). FDA decision 3/30/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-30
OutcomeApproved
Drug / candidatePONLIMSI (denosumab-adet) (biosimilar to Pro
CompanyTeva Pharmaceutical Industries Limited A
120-day run-up (T-120→T-1)+44.0%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio